ALFA Finder| Revenue growth | 116.3% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margins expanded significantly to 35.5% due to high-value CMS mix. |
| Order book | Growth in new project orders for delivery this/next FY. |
| Demand visibility | Strong traction from Innovators with peptides in the pipeline. |
| Management confidence | CEO notes strong customer conversations and capability-led discussions. |
Growth
PAT grew 975% YoY to ₹147.4 Cr; EBITDA surged 448% YoY to ₹231.1 Cr.
Outlook
Capex outflow of ₹122 Cr in Q1FY27; ongoing investment in a new peptide facility.
Risks
Potential timeline delays in pipeline projects and impact of raw material price volatility.
Last quarter's promises, checked
Delivered
- Guided FY26 strong growth vs FY24 → Delivered ₹2053.1 Cr revenue (+37.1% YoY) (= BEAT)
- Guided FY26 EBITDA margin expansion → Delivered 29.4% vs 22.9% YoY (= BEAT)
- Guided peptide facility ready by July 2026 → On track for July operation (= BEAT)
Partly delivered
- Guided 18-20% long-term CAGR → Delivered 116.3% in Q1FY27 (lumpy/non-linear) (= PARTIAL)
Missed
- Guided working capital normalization → Delivered 137 days vs 107 days YoY (= MISS)
Investor Presentation filed with BSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹20,404.00
- Market cap
- ₹26,178 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 57.9×Sector 43.8×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q2 income and EBITDA fell sharply YoY, and PAT dropped 47%. Management blames commercial lumpiness, says H1 was in line, and declined to quantify FY27 growth or give molecule-level detail.
Neuland Laboratories Investor Presentation: Key Takeaways
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Q2 FY27 Results: Net Profit ₹51.6 Cr, Down 46.7% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹449.7 Cr (-12.6% YoY) and net profit of ₹51.6 Cr (-46.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.6 Cr · -46.7% YoY
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.